ILEX Oncology Inc.'s drug eflornithine (DFMO) failed to reach statistical significance in a Phase III trial with superficial bladder cancer patients, resulting in the company's decision to discontinue development. (BioWorld Today) Read More
BioWorld Today's offices were closed Monday, Jan. 19, in observance of the Martin Luther King Jr. holiday in the U.S. and no issue was published that day. Read More
